Table 2 Selected completed immunotherapy trials in treatment-naïve NSCLC
From: The next generation of immunotherapy: keeping lung cancer in check
Completed trial name | Phase | Histology | Therapy | mORR (%) | <1% PD-L1 ORR | >1% PD-L1 ORR | >50% PD-L1 ORR | <1% PD-L1 PFS | >1% PD-L1 PFS | >50% PD-L1 PFS | Ref |
 CheckMate 012 | 1 | ALL | NIVO3 | 23 | 14 | 28 | 50 | 6.6 | 3.5 | 8.4 | |
NIVO3 + IPIQ12W | 47 | 30 | 57 | 100 | 4.7 | 8.1 | 13.6 |  | |||
NIVO3 + IPIQ6W | 39 | 0 | 57 | 86 | 2.4 | 10.6 | NR |  | |||
Trial Name | Phase | Histology | Therapy | PFS (months) | 6-month OS (%) | ORR (%) | DOR | TrAEs (%) | 3 + TrAEs (%) |  |  |
 KEYNOTE-024 | 3 | ≥50% PD-L1 | PEMBROQ3W | 10.3 | 80.2 | 44.8 | NR | 73.4 | 26.6 |  | [21] |
PT-DC | 6.0 | 72.4 | 27.8 | 6.3months | 90.0 | 53.3 | |||||
Trial name | Phase | Histology | Therapy | PFS (months) | OS | ORR | DOR | TrAEs (%) | 3 + TrAEs (%) |  |  |
 CheckMate 026 | 3 | ≥5% PD-L1 | NIVO3 | 4.2 | pending | pending | pending | 71 | 18 |  | [60] |
PT-DC | 5.9 | pending | pending | pending | 92 | 51 | Â |